ArticleClinical kidney journal2026
Acetate-free dialysate, protein-energy wasting, and muscle outcomes in maintenance hemodialysis: a randomized-controlled trial.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Protein-energy wasting and muscle atrophy are common in maintenance hemodialysis and linked to adverse outcomes. Acetate from acetic acid-containing dialysate concentrate may promote inflammation and metabolic disturbances. We evaluated whether acetate-free dialysate prepared from a hydrochloric acid-containing concentrate could improve nutritional status and muscle-related outcomes in chronic hemodialysis patients. Methods: In this single-center, single-blind, randomized crossover trial, adults receiving maintenance hemodialysis were assigned to acetate-free or acetate-containing dialysate for 6 months, followed by crossover to the alternate dialysate for an additional 6 months. The primary endpoint was serum prealbumin. Secondary endpoints included body composition assessed by bioimpedance spectroscopy, handgrip strength, 4-m gait speed, SARC-F score, serum albumin, and C-reactive protein. Outcomes were analyzed using linear mixed-effects models adjusted for period and treatment sequence, with patient included as a random effect. Results: Sixty patients were included. The mean age was 68.8 ± 9.4 years, and 72.4% were male. Prealbumin concentrations remained stable with acetate-containing dialysate, from 0.291 ± 0.079 g/l at baseline to 0.287 ± 0.076 g/l at month 6, and with acetate-free dialysate, from 0.294 ± 0.085 to 0.279 ± 0.074 g/l. The dialysate-by-time interaction was not significant ( Conclusion: In this randomized crossover trial, acetate-free dialysate did not improve nutritional and muscle status compared with conventional acetate-containing dialysate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.